Skip to Content
PharmaceuticalsPharmaceuticals
  • Editor’s Choice
  • Review
  • Open Access

25 December 2025

24 Pages

Puberty Starts in the Gut: Intestinal Clues to Early Puberty-Rethinking Biomarkers in Pediatric Endocrinology

,
,
,
,
,
,
,
,
and
1
Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, Romania
2
Endocrinology Department, Saint Spiridon County Hospital, 700111 Iași, Romania
*
Author to whom correspondence should be addressed.

Abstract

Central precocious puberty (CPP) may be influenced by gut microbiota through changes in short-chain fatty acids (SCFAs), β-glucuronidase activity, and enterohepatic estrogen recycling. This narrative review integrates current evidence from human and animal studies exploring microbial contributions to pubertal timing. Across multiple cohorts, CPP is associated with loss of SCFA-producing commensals, such as Bacteroides, and increased abundance of taxa like Alistipes, Ruminococcus, and Lachnoclostridium. These microbial shifts are linked to altered SCFA profiles, diminished anti-inflammatory and neuroendocrine modulation, and enhanced reabsorption of estrogens via microbial β-glucuronidase activity. Experimental models support a causal connection: gut dysbiosis accelerates pubertal onset, whereas microbiota-targeted interventions can restore hormonal balance and delay activation of the HPG axis. While some overlap with obesity-associated microbiota exists, the endocrine-specific microbial changes observed in CPP suggest partially distinct mechanisms. Overall, the gut microbiota emerges as both a modulator and potential biomarker of early pubertal onset. Its integration into pediatric endocrine frameworks could improve early risk assessment and guide future interventions, though further validation through standardized, longitudinal, and diverse population studies is still required.

1. Introduction

The timing of pubertal onset is a tightly regulated process governed by the hypothalamic–pituitary–gonadal (HPG) axis, traditionally viewed through the lens of neuroendocrine and genetic regulation [1,2]. However, in recent years, a growing body of research has begun to challenge this classical paradigm, suggesting that signals arising from the gastrointestinal tract, particularly those mediated by the gut microbiota, may play a critical role in shaping endocrine transitions [3]. Among these, the possibility that gut microbial components or metabolites could serve as early, non-invasive biomarkers of pubertal onset or dysregulation is gaining increasing attention in pediatric endocrinology [3,4].
The concept of the gut–brain–gonad axis introduces a new layer of complexity to our understanding of pubertal regulation. Gut microorganisms and their byproducts, such as short-chain fatty acids (SCFAs), inflammatory mediators, and estrogen-modifying enzymes (e.g., β-glucuronidase) have been implicated in modulating key processes related to sexual maturation [3,5]. Notably, these microbial signals may influence the timing and progression of puberty through pathways involving systemic inflammation, energy metabolism, and direct neuroendocrine interactions at the level of the hypothalamus [6,7].
Central precocious puberty (CPP), defined as the premature activation of the HPG axis, presents an ideal clinical model for exploring these gut-derived influences [8]. Emerging evidence suggests that children with CPP exhibit distinct alterations in gut microbial composition compared to age-matched peers [8,9]. These changes, often linked to obesity, dietary patterns, antibiotic exposure, and immune activation, raise the question of whether specific microbial profiles or functional signatures could serve as predictive or diagnostic biomarkers of early puberty [9,10,11].
This review aims to critically evaluate current evidence linking the gut microbiota to pubertal development, with a specific focus on its potential as a biomarker platform for early pubertal onset. We explore mechanistic pathways through which microbial taxa, enzymes, and metabolites may interact with the HPG axis, highlight early-life factors that shape microbial architecture and pubertal timing and assess the strengths and limitations of current human and animal studies. Finally, we outline key research gaps and propose future directions for integrating microbiome-based diagnostics into clinical pediatric endocrinology.
Given the heterogeneity of available evidence, it was essential to outline the approach used in selecting the literature for this narrative review. To contextualize the evidence synthesized, we performed a broad, nonsystematic search of the literature examining the relationship between gut microbiota and pubertal development. The search was conducted across major biomedical databases, including PubMed, Scopus, Web of Science, and Google Scholar, and focused on studies published between January 2020 and September 2025. This interval was selected because research on the gut microbiota–endocrine interface expanded substantially after 2020, driven by advances in sequencing technologies, microbial functional profiling, and improved analytical standards. Earlier influential studies were also considered when identified through the reference lists of key publications. We prioritized research that investigated gut microbial composition or functional activity in relation to central precocious puberty or early pubertal onset, in either human cohorts or relevant animal models, and that provided quantitative or mechanistic insights involving endocrine markers such as LH, FSH, or estradiol. Studies focusing exclusively on male puberty, unrelated endocrine disorders, or metabolic conditions without pubertal assessment were not considered central to the aims of this synthesis, nor were those lacking microbiota profiling or functional microbial analyses. Literature retrieval relied on combinations of terms such as “gut microbiota,” “intestinal microbiome,” “intestinal flora,” “precocious puberty,” “early puberty,” “pubertal timing,” “girls,” and “children,” ensuring coverage of both compositional and functional dimensions. No language-based restrictions were applied in order to minimize selection bias and to obtain a comprehensive and globally representative overview of current research in this evolving field.

2. Neuroendocrine Modulators of Pubertal Timing: A Framework for Microbiota Interactions

The initiation of puberty is orchestrated by the activation of the hypothalamic–pituitary–gonadal axis, triggered by increased pulsatility of gonadotropin-releasing hormone (GnRH) secretion from specialized hypothalamic neurons. This, in turn, stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), promoting gonadal maturation and sex steroid production [12,13,14]. While the sequence of events is well defined, the upstream triggers of GnRH pulsatility remain incompletely understood.
Among the most critical regulators is the kisspeptin system, which serves as a central integrator of metabolic and hormonal signals. Peripheral cues such as leptin, insulin, IGF-1, ghrelin, and cortisol modulate kisspeptin neurons, thereby linking nutritional and stress-related states to pubertal onset [15,16,17]. In particular, leptin, a hormone secreted by adipose tissue, acts permissively by signaling adequate energy reserves to the hypothalamus [18,19]. Leptin deficiency results in pubertal failure, while hyperleptinemia, commonly observed in childhood obesity, is associated with earlier pubertal onset, albeit modulated by leptin resistance and inflammation [20].
Systemic low-grade inflammation, often driven by excess adiposity or metabolic stress, further influences pubertal timing by disrupting leptin signaling and impairing GnRH regulation [21,22]. Cytokines such as IL-6 and TNF-α have been shown to interfere with hypothalamic function and reproductive hormone secretion [23,24].
These neurometabolic and immune pathways are increasingly recognized as key points of interaction with the gut microbiota. Gut-derived signals including SCFAs, cytokine modulators, and estrogen-metabolizing enzymes may influence pubertal development through their effects on metabolic homeostasis, inflammatory tone, and neuroendocrine signaling [25,26].

3. Precocious Puberty in Girls: The Clinical Relevance of Early Biomarkers

Central precocious puberty is defined by the premature activation of the HPG axis, with the onset of secondary sexual characteristics before the age of 8 in girls. Although the endocrine cascade remains intact, its early initiation has profound implications, including accelerated bone maturation, compromised adult height, and psychosocial disorders [27,28]. It not only affects their adult height and psychological well-being but also increases the risk of various diseases in the adulthood including hypertension, stroke, ischemic heart disease, type 2 diabetes and estrogen dependent cancer [29,30,31,32].
The global rise in CPP incidence, particularly in urbanized populations, has prompted investigations into modifiable environmental and biological contributors [33,34,35]. While known factors include obesity, endocrine-disrupting chemicals (EDCs), and psychosocial stress, increasing attention is being directed toward the gut microbiota as both a modulator and potential early biomarker of pubertal timing [36,37,38,39,40].
Microbial signatures associated with CPP may reflect underlying alterations in inflammation, estrogen metabolism, or energy signaling all of which intersect with established neuroendocrine regulators. Thus, profiling the gut microbiota offers a promising, non-invasive approach to identifying children at risk of early pubertal onset and to guiding personalized interventions [41,42,43].
Idiopathic central precocious puberty (ICPP) denotes GnRH-dependent early activation of the HPG axis without an identifiable CNS lesion. It accounts for most CPP cases in girls and is characterized by progressive thelarche, growth-spurt, and advanced bone age [44]. Diagnosis rests on a pubertal-range LH (basal or after a GnRH/GnRH-agonist stimulation test), supportive estradiol levels, and, when used, pelvic ultrasound showing increased uterine/ovarian volume with follicles [30,45,46]. The GnRH stimulation test represents the gold standard test for differentiation between CPP and peripheral precocious puberty. If the LH peak (after 120 min after the GnRH analog injection) is higher than 5 IU/L and the FSH/LH ratio is higher than 0,6 a diagnosis of CPP is made [30,47]. Given the discomfort associated with the test, there is a pressing need to advance non-invasive strategies. Stool-based candidates, including gut microbiota composition changes and related profiles, offer a promising direction.
Standard treatment is long-acting GnRH analogs (leuprolide, triptorelin), which suppress gonadotropins and improve predicted adult height while easing psychosocial strain [48,49]. Although effective, standard approaches involve frequent injections that can be painful and distressing, undermining compliance, increasing costs, and potential adverse reactions including transient vaginal bleeding, allergic reactions, and local sterile abscesses that may reduce treatment effectiveness [50]. Optimizing existing strategies for CPP is therefore urgent to enhance acceptability in children. Emerging stool-based interventions, particularly probiotics and fecal microbiota transplantation, warrant rigorous evaluation as less invasive options. Ultimately, the gut microbiome’s influence on endocrine signaling highlights its relevance to future therapy design [51].
Against this background, early, non-invasive biomarkers (such as gut-microbiota–based signatures) are clinically appealing to flag at-risk girls before unequivocal signs, prioritize referral, and avoid unnecessary imaging or delayed therapy [38].

4. Development and Maturation of the Gut Microbiota: Evolution Across the Lifespan

The human gut microbiota undergoes substantial changes throughout life, influenced by host genetics, diet, environment, immune function, and hormonal status. Understanding the developmental trajectory of the gut microbiota is critical to elucidating its potential role in regulating systemic processes such as immunity, metabolism, and endocrine function including its emerging association with pubertal timing [52,53].
The first 1000 days of life, spanning gestation through the second year, are now recognized as a critical window for microbial programming of host physiology. During this period, the gut microbiota interacts intimately with the developing immune system, helping establish tolerance to self and environmental antigens while educating mucosal and systemic immune responses. Dysbiosis during this window, whether due to cesarean section, formula feeding, or antibiotics, has been associated with an increased risk of allergic, autoimmune, and metabolic disorders [8,54,55].
Importantly, while the microbiota remains plastic during infancy and early childhood, early perturbations may lead to long-term alterations in microbial architecture and function [52,56].
From childhood to adolescence, the GM switches from a diet-shaped ‘plateau’ to a community that also reflects endocrine maturation (Figure 1). In school-age children the alpha diversity is already high and often remains stable or rises slightly as diets modify; moreover, the beta-diversity tends to widen with diverging eating patterns, adiposity and activity levels [57]. As girls enter puberty, sex steroids (especially estradiol activity), insulin/leptin mechanisms and IGF-1 reshape the intestinal milieu and a set of reproducible microbial tendencies emerges across cohorts: the community shifts towards Firmicutes-rich families (Lachnospiraceae and Ruminococcaceae). Some studies also note that the dominant taxa are Clostridia and Bacteroidia and the major element suggesting maturation of the microbiota is represented by a switch in the dominance of the Clostridiales and Bacteroidales classes of bacteria. During puberty, there is a progressive enrichment of Clostridiales accompanied by a reduction in Bacteroidales, bringing the gut microbiota closer to the adult composition. At the phylum level, Firmicutes increase across puberty, whereas Bacteroidetes decline [58,59,60,61].
Figure 1. Lifespan trajectory of the gut microbiota. Infancy is characterized by low diversity with Bifidobacterium dominance in breastfed infants [8,55]; childhood shows high alpha diversity and a diet-shaped plateau [52]; during puberty (girls) there is enrichment of Clostridiales, increases in Lachnospiraceae/Ruminococcaceae, a subset-specific decline in Bacteroidales, and higher fecal β-glucuronidase activity, with Alistipes increasing [4,58,62].
The estrobolome, the set of microbial functions that deconjugate estrogens, also shows pubertal dynamics. Several pediatric cohorts report higher fecal β-glucuronidase activity during puberty, particularly when pathobionts such as Klebsiella and Escherichia/Shigella expand. Increased deconjugation favors intestinal reabsorption of estrogens via the enterohepatic cycle, potentially amplifying estrogen exposure once central activation has begun. This estrobolome imprint sits alongside SCFA changes and adds an endocrine-proximal mechanism by which the gut community can influence pubertal physiology [4,58].
Taken together, the physiologic maturation of the gut microbiota in girls marked by a modest shift toward Firmicutes, a relative decline of Bacteroides in a subset and Lachnospiraceae/Ruminococcaceae genera, and a measurable rise in fecal β-glucuronidase sets the background against which ICPP emerges. Case–control studies show the same axes in CPP but earlier and with greater amplitude (Bacteroides ↓, Alistipes ↑, cohort-variable Faecalibacterium/Roseburia, β-glucuronidase ↑). This amplification aligns CPP with pubertal physiology while departing from age norms, and it supports the use of stool-based, puberty-proximal features as early risk indicators [62,63,64,65,66].

5. Mechanistic Pathways Linking Gut Microbiota to Pubertal Regulation

The gut microbiota exerts profound systemic effects on host physiology, extending well beyond the gastrointestinal tract. In recent years, growing evidence has highlighted its potential role in modulating the HPG axis, suggesting a key function in regulating pubertal timing and progression. Several mechanistic pathways have been proposed through which the gut microbiota may influence endocrine, immune, and metabolic systems involved in pubertal development, particularly in the context of CPP [67,68,69].
Among the various mechanisms proposed to link the gut microbiota with pubertal regulation, two pathways have emerged as particularly relevant in the female pubertal trajectory: the estrobolome, through its influence on estrogen metabolism, and microbial production of SCFAs, which act as endocrine modulators of neuroimmune and hypothalamic function [70,71]. These interconnected axes represent the most biologically plausible and currently best supported mechanisms explaining microbiota-driven modulation of pubertal timing [72,73].

5.1. The Estrobolome and Estrogen Metabolism

The estrobolome represents the subset of the gut microbiota that possesses the capacity to metabolize estrogens primarily through the action of bacterial β-glucuronidase enzymes. These enzymes deconjugate estrogen conjugates that have been metabolized by the liver and excreted into the bile, allowing free estrogens to be reabsorbed into the circulation via enterohepatic recirculation. This microbial function plays a critical role in maintaining systemic estrogen homeostasis [58,60].
In physiological conditions, estrogens are metabolized hepatically through conjugation which facilitates their excretion into the intestinal lumen via bile. However, in the colon, β-glucuronidase-expressing bacteria, for example species within the genera Bacteroides, Clostridium, Escherichia, and Lactobacillus, can reverse this process, liberating active estrogens [52]. These unconjugated estrogens can then be reabsorbed across the intestinal epithelium, re-entering systemic circulation and contributing to the bioavailable estrogen. This mechanism of microbial-mediated estrogen recycling has been well documented in adult women, where it contributes to hormonal balance and may be dysregulated in conditions such as estrogen-sensitive cancers and metabolic syndrome [58,62]. However, its relevance to pubertal timing is now becoming increasingly apparent, particularly in the context of CPP, where estrogen exposure is prematurely elevated. In fact, studies comparing the gut microbiota of girls with ICPP to age-matched prepubertal controls have identified increased abundance of Escherichia coli and Clostridium spp., genera known to harbor high β-glucuronidase activity [52,74]. Although the directionality and causality of this relationship remain to be clarified, such findings support the hypothesis that an overactive estrobolome may contribute to premature estrogen-driven maturation.
The activity of the estrobolome is not solely dependent on microbial composition, but also on host and environmental factors. Dietary components such as fiber, phytoestrogens, and polyphenols can modulate the activity and expression of β-glucuronidase [5,75]. Moreover, early-life exposure to antibiotics, which disrupt microbial diversity and reduce β-glucuronidase-expressing taxa, has been associated with both delayed and accelerated pubertal patterns, further underscoring the complexity of the microbiota–estrogen axis [9]. Additionally, inflammatory signals in the gut microenvironment may influence the estrobolome through epigenetic regulation of bacterial gene expression or shifts in metabolic niche competition [76]. For example, inflammatory conditions such as obesity or dysbiosis-induced gut permeability can alter the functional capacity of the microbiota, leading to increased estrogen recirculation in a pro-inflammatory setting, which may further sensitize the HPG axis [22,25,77].

5.2. Short Chain Fatty Acids (SCFAs) and Neuroendocrine Modulation

SCFAs are small organic molecules generated mainly through the bacterial fermentation of dietary carbohydrates. The most abundant are acetate, propionate, and butyrate, while isobutyrate, valerate, and isovalerate are produced in smaller amounts. Their biosynthesis is largely attributed to colonic taxa such as Bifidobacterium, Lactobacillus, Roseburia, Coprococcus, Faecalibacterium, and members of the Lachnospiraceae family [65]. Beyond serving as an energy source for colonocytes, SCFAs exert wide-ranging effects on host physiology, including pathways relevant to pubertal development [78].
Mechanistically, SCFAs interact with the gut–brain axis by binding to receptors on intestinal endocrine cells, immune cells, and neurons, thereby influencing host gene expression. One key target is the regulation of genes encoding cAMP response element–binding proteins, which in turn modulate catecholamine biosynthesis. This includes enhancing tyrosine hydroxylase activity (the rate-limiting step in dopamine synthesis) while reducing expression of dopamine β-hydroxylase, the enzyme responsible for converting dopamine into norepinephrine. As a result, SCFAs can shape dopaminergic tone, a pathway closely linked with hypothalamic regulation of reproduction [16,17]. In addition, they modulate neurotransmitter signaling more broadly, including serotonin and dopamine, providing another layer of interaction between the gut microbiota and the central neuroendocrine circuits governing pubertal timing [78].
Among the best characterized SCFAs, butyrate stands out due to its pleiotropic effects on host physiology, ranging from energy metabolism and obesity to immune regulation, neural function and carcinogenesis. This metabolite is mainly produced by colonic bacteria such as Faecalibacterium prausnitzii (Clostridium cluster IV) and Roseburia spp. (Clostridium cluster XIV), though butyrate-producing capacity is also distributed across other clusters, including IX, XV, XVI and XVII [52].
Perturbations in butyrate-producing populations have been implicated in altered timing through several mechanisms. First, butyrate binds preferentially to G-protein coupled receptor 41 (GPR41), which enhances leptin expression. Leptin, in turn, regulates kisspeptin neurons and facilitates the pulsatile secretion of GnRH, a central driver of pubertal initiation [79,80]. Second mechanism, through epigenetic pathways, butyrate increases the proportion of cholinergic enteric neurons, thereby modulating acetylcholine signaling and adding another layer of gut–brain communication relevant to pubertal onset [81]. The third one, butyrate stimulates glucagon-like peptide-1 (GLP-1) release, leading to increased insulin secretion; insulin subsequently promotes GnRH gene transcription in the hypothalamus (Figure 2) [78].
Figure 2. Proposed mechanisms linking gut microbiota to early pubertal onset.
While butyrate has attracted particular attention, the overall balance between the major SCFAs (acetate, propionate, and butyrate) also plays a crucial role in host physiology and may influence pubertal development [78]. These metabolites are produced in varying proportions depending on diet, microbiota composition, and metabolic status. Acetate and propionate are strongly linked to energy harvest and lipogenesis, and elevated levels have been associated with obesity and low-grade systemic inflammation, both of which are known modulators of pubertal timing [12]. In contrast, butyrate exerts predominantly anti-inflammatory and epigenetic effects that support intestinal and neuroendocrine homeostasis [82,83]. Thus, an imbalance characterized by relative depletion of butyrate-producing taxa and excess acetate/propionate production may create a pro-inflammatory and insulin-resistant milieu that facilitates premature activation of the hypothalamic–pituitary–gonadal axis. This highlights that not only the absolute levels of specific SCFAs, but also their ratios, are likely to be critical determinants linking gut microbial metabolism with the timing of puberty [12].
Although mechanistic studies suggest that butyrate may directly stimulate neuroendocrine pathways involved in pubertal initiation, clinical data in girls with CPP point to a different pattern. Case–control analyses consistently report a reduction in butyrate-producing taxa (Faecalibacterium, Coprococcus) accompanied by elevated acetate levels [64]. This imbalance results in the loss of butyrate’s protective anti-inflammatory and epigenetic functions, while excess acetate favors a pro-inflammatory and insulin-resistant state. Together, these changes create a permissive environment for premature activation of the hypothalamic–pituitary–gonadal axis, thus providing a plausible link between gut microbiota composition and altered pubertal timing in CPP. These insights underscore the potential of SCFA profiling as a non-invasive biomarker approach in assessing pubertal risk and pave the way for therapeutic interventions targeting the gut microbiome [64,78].

7. Conflicting Evidence and Remaining Gaps

The current body of evidence linking gut microbiota to CPP remains fragmented and, at times, contradictory. Some cohorts consistently report a depletion of butyrate-producing taxa such as Faecalibacterium and Anaerostipes [8], while others describe an enrichment of alternative SCFA-producing species, including multiple Bacteroides species, Parabacteroides, and Ruminococcus [42]. This inconsistency extends to functional findings as well: although increased β-glucuronidase activity is a recurring observation, its causal role in estrogen reactivation and pubertal acceleration remains debated [41]. Such discrepancies highlight the complexity of microbiota–host interactions and emphasize the need for cautious interpretation. Adding to this complexity, recent findings indicate that PPP may represent an intermediate stage between CPP and healthy children. Overlapping alterations in gut microbiota composition have been observed in both PPP and CPP cohorts suggesting these endocrine phenotypes may reflect points along a continuum rather than distinct entities [52]. This raises important questions regarding the pathophysiological overlap and potential sequential progression between peripheral and central forms of precocious puberty, which remain insufficiently understood.
Despite growing interest, significant limitations still constrain this field. Most available human studies are cross-sectional and observational, restricting causal inference; even consistent findings such as Bacteroides depletion and propionate shortfall should be regarded as associations rather than proven mechanisms [40]. Human cohorts are heterogeneous in dietary background, ethnicity, and sequencing methodology (16S rRNA vs. shotgun metagenomics), which complicates direct comparison and likely contributes to conflicting results. The predominance of Asian cohorts further limits generalizability, since gut microbiota composition differs markedly across populations, with Asian children often exhibiting higher Bifidobacterium abundance than their Western peers [99]. Cohort sizes are also relatively small and single-center, raising concerns about statistical power and external validity [99].
Mechanistic insights, although compelling, rely heavily on animal models. While such experiments establish causality, they cannot replicate the timing and complexity of human pubertal physiology, making direct extrapolation from rodents to children problematic [15,51,55]. Additional challenges arise from uncontrolled confounders—diet, BMI, antibiotic exposure, and socioeconomic context—that blur the distinction between microbiota-specific effects and broader environmental influences [60]. Furthermore, functional readouts such as fecal SCFA levels or estrobolome activity were inconsistently assessed, despite being central to mechanistic interpretation. Finally, the absence of large, multicenter, longitudinal studies with standardized protocols integrating microbiota, metabolomics, and endocrine profiling continues to delay translation into clinical practice and hinders the development of robust biomarkers for CPP risk prediction [52].
Addressing these inconsistencies through well-designed, longitudinal, and multi-ethnic studies will be essential to determine whether gut microbiota can truly serve as a reliable biomarker for CPP risk prediction. Beyond diagnostics, confirming a causal role would also open the door to microbiota-targeted interventions such as dietary modulation, prebiotics or probiotics offering novel strategies to delay or prevent premature pubertal onset.

8. Future Perspectives

Advancing our understanding of the gut microbiota’s role in pubertal timing may open new therapeutic frontiers in pediatric endocrinology. While most current studies have focused on observational associations, emerging insights into microbial metabolites and host metabolic signaling suggest that the microbiota could evolve from a passive biomarker into an active therapeutic target. Strategically modifying GM composition may ultimately complement existing therapies that suppress hypothalamic activation.
One promising direction is the development of microbiota-targeted interventions, including dietary and pharmacological strategies designed to restore microbial homeostasis. Among these, dietary polyphenols, notably epigallocatechin gallate (EGCG), a green tea catechin, are of growing interest. According to Rodríguez-Daza and colleagues, certain polyphenols display a “duplibiotic” effect—a dual ability to suppress pathobionts while enriching beneficial microbes such as Akkermansia muciniphila. In animal models, EGCG supplementation has been shown to enhance gut barrier integrity, reduce inflammatory signaling, and increase Akkermansia abundance, features highly relevant to pubertal timing and endocrine balance [116,117]. Other microbiota-directed strategies, such as probiotic supplementation and fecal microbiota transplantation (FMT), also warrant consideration. While these remain experimental in pediatric populations, their potential to recalibrate host–microbiome interactions and modulate gut–brain and gut–endocrine axes may provide future adjuncts to standard endocrine therapies [78,118].
Translating these findings into clinical impact will require mechanistically driven, longitudinal studies that integrate microbiome, metabolomic, and endocrine profiling in ICPP cohorts. Moving beyond descriptive correlations, such work could redefine how we approach the prevention and treatment of early pubertal onset, positioning the gut microbiota not only as a modulator of timing, but as a modifiable therapeutic frontier.

9. Conclusions

This review underscores the emerging role of the gut microbiota in central precocious puberty, highlighting three recurring mechanisms: a consistent loss of propionate-producing taxa such as Bacteroides, enrichment of β-glucuronidase–positive microbes that enhance estrogen recirculation, and context-dependent shifts in butyrate producers. While these features overlap partially with obesity-associated dysbiosis, the CPP microbiome is distinguished by stronger endocrine coupling, reflected in links to LH/estradiol, kisspeptin/GnRH activity, and estrobolome function. From a clinical perspective, the gut microbiota should not yet be viewed as a stand-alone diagnostic marker, but stool-based microbial signatures, when combined with endocrine and clinical parameters, may provide a non-invasive tool for early risk stratification.

Author Contributions

Conceptualization T.C.V. and O.E.F.; methodology, I.V., V.Ș., A.R. and O.R.T.; writing—original draft preparation, T.C.V.; writing—review and editing, E.J., A.I. and I.D.I.; visualization, A.F. and I.V.; supervision, O.E.F. and A.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
cAMPCyclic adenosine monophosphate
CNSCentral nervous system
CPPCentral precocious puberty
EDCsEndocrine-disrupting chemicals
EGCGEpigallocatechin Gallate
FFAR2Free fatty acid receptor 2
FFAR3Free fatty acid receptor 3
FMTFecal microbiota transplatation
FSHFollicle stimulating hormone
F/BFirmicutes to Bacteroidetes
GLP-1Glucagon-like peptide-1
GMGut microbiota
GnRHGonadotropin-releasing hormone
GPR41G-protein coupled receptor 41
HFDHigh-fat diet
HPGHypothalamic-pituitary-gonadal
ICPPIdiopathic central precocious puberty
LHLuteinizing hormone
LHRHLuteinizing hormone-releasing hormone
NONitric oxide
norDCA23-nordeoxycholic acid
OPPObesity-complicated precocious puberty
PPPrecocious puberty
PPPPeripheral precocious puberty
PYYPeptide YY
ROSReactive oxygen species
SCFAsShort-chain fatty acids

References

  1. Mancini, A.; Magnotto, J.C.; Abreu, A.P. Genetics of Pubertal Timing. Best Pract. Res. Clin. Endocrinol. Metab. 2022, 36, 101618. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Abreu, A.P.; Kaiser, U.B. Pubertal Development and Regulation. Lancet Diabetes Endocrinol. 2016, 4, 254–264. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Yue, M.; Zhang, L. Exploring the Mechanistic Interplay between Gut Microbiota and Precocious Puberty: A Narrative Review. Microorganisms 2024, 12, 323. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Hu, S.; Ding, Q.; Zhang, W.; Kang, M.; Ma, J.; Zhao, L. Gut Microbial Beta-Glucuronidase: A Vital Regulator in Female Estrogen Metabolism. Gut Microbes 2023, 15, 2236749. [Google Scholar] [CrossRef] [Scilit]
  5. Baker, J.M.; Al-Nakkash, L.; Herbst-Kralovetz, M.M. Estrogen–Gut Microbiome Axis: Physiological and Clinical Implications. Maturitas 2017, 103, 45–53. [Google Scholar] [CrossRef] [Scilit]
  6. Qian, Y.; Fang, X.; Chen, Y.; Ding, M.; Gong, M. Gut Flora Influences the Hypothalamic-Gonadal Axis to Regulate the Pathogenesis of Obesity-Associated Precocious Puberty. Sci. Rep. 2024, 14, 28844. [Google Scholar] [CrossRef] [Scilit]
  7. Kim, S.J.; Kim, J.H.; Hong, Y.H.; Chung, I.H.; Lee, E.B.; Kang, E.; Kim, J.; Yang, A.; Rhie, Y.-J.; Yoo, E.-G.; et al. 2022 Clinical Practice Guidelines for Central Precocious Puberty of Korean Children and Adolescents. Ann. Pediatr. Endocrinol. Metab. 2023, 28, 168–177. [Google Scholar] [CrossRef] [Scilit]
  8. Wang, L.; Yi, Q.; Xu, H.; Liu, H.; Tan, B.; Deng, H.; Chen, Y.; Wang, R.; Tang, F.; Cheng, X.; et al. Alterations in the Gut Microbiota Community Are Associated with Childhood Obesity and Precocious Puberty. BMC Microbiol. 2024, 24, 311. [Google Scholar] [CrossRef] [Scilit]
  9. Hu, Y.; Li, J.; Yuan, T.; Yu, T.; Chen, Y.; Kong, H.; Lin, C.; Shen, Z.; Tian, Y.; Tong, S.; et al. Exposure to Antibiotics and Precocious Puberty in Children: A School-Based Cross-Sectional Study in China. Environ. Res. 2022, 212, 113365. [Google Scholar] [CrossRef] [Scilit]
  10. Tzounakou, A.-M.; Stathori, G.; Paltoglou, G.; Valsamakis, G.; Mastorakos, G.; Vlahos, N.F.; Charmandari, E. Childhood Obesity, Hypothalamic Inflammation, and the Onset of Puberty: A Narrative Review. Nutrients 2024, 16, 1720. [Google Scholar] [CrossRef] [Scilit]
  11. Korpela, K.; Kallio, S.; Salonen, A.; Hero, M.; Kukkonen, A.K.; Miettinen, P.J.; Savilahti, E.; Kohva, E.; Kariola, L.; Suutela, M.; et al. Gut Microbiota Develop towards an Adult Profile in a Sex-Specific Manner during Puberty. Sci. Rep. 2021, 11, 23297. [Google Scholar] [CrossRef] [Scilit]
  12. You, X.; Yang, W.; Li, X.; Li, X.; Huang, Y.; Huang, C. Dietary Modulation of Pubertal Timing: Gut Microbiota-Derived SCFAs and Neurotransmitters Orchestrate Hypothalamic Maturation via the Gut–Brain Axis. J. Endocrinol. Investig. 2025, 48, 2229–2248. [Google Scholar] [CrossRef] [Scilit]
  13. Pedro, M.; Adriana, D.S.L.; Karolina, S. Physiology of GnRH and Gonadotrophin Secretion. In Endotext [Internet]; MDText.com, Inc.: South Dartmouth, MA, USA, 2024. [Google Scholar]
  14. Spaziani, M.; Tarantino, C.; Tahani, N.; Gianfrilli, D.; Sbardella, E.; Lenzi, A.; Radicioni, A.F. Hypothalamo-Pituitary Axis and Puberty. Mol. Cell. Endocrinol. 2021, 520, 111094. [Google Scholar] [CrossRef] [Scilit]
  15. Wang, L.; Xu, H.; Tan, B.; Yi, Q.; Liu, H.; Deng, H.; Chen, Y.; Wang, R.; Tian, J.; Zhu, J. Gut Microbiota and Its Derived SCFAs Regulate the HPGA to Reverse Obesity-Induced Precocious Puberty in Female Rats. Front. Endocrinol. 2022, 13, 1051797. [Google Scholar] [CrossRef] [Scilit]
  16. Anderson, G.M.; Hill, J.W.; Kaiser, U.B.; Navarro, V.M.; Ong, K.K.; Perry, J.R.B.; Prevot, V.; Tena-Sempere, M.; Elias, C.F. Metabolic Control of Puberty: 60 Years in the Footsteps of Kennedy and Mitra’s Seminal Work. Nat. Rev. Endocrinol. 2024, 20, 111–123. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Navarro, V.M. Metabolic Regulation of Kisspeptin—The Link between Energy Balance and Reproduction. Nat. Rev. Endocrinol. 2020, 16, 407–420. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Koysombat, K.; Tsoutsouki, J.; Patel, A.H.; Comninos, A.N.; Dhillo, W.S.; Abbara, A. Kisspeptin and Neurokinin B: Roles in Reproductive Health. Physiol. Rev. 2025, 105, 707–764. [Google Scholar] [CrossRef] [Scilit]
  19. Iwasa, T.; Minato, S.; Imaizumi, J.; Yoshida, A.; Kawakita, T.; Yoshida, K.; Yamamoto, Y. Effects of Low Energy Availability on Female Reproductive Function. Reprod. Med. Biol. 2022, 21, e12414. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Farooqi, I.S.; Jebb, S.A.; Langmack, G.; Lawrence, E.; Cheetham, C.H.; Prentice, A.M.; Hughes, I.A.; McCamish, M.A.; O’Rahilly, S. Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency. N. Engl. J. Med. 1999, 341, 879–884. [Google Scholar] [CrossRef] [Scilit]
  21. Farooqi, I.S.; Wangensteen, T.; Collins, S.; Kimber, W.; Matarese, G.; Keogh, J.M.; Lank, E.; Bottomley, B.; Lopez-Fernandez, J.; Ferraz-Amaro, I.; et al. Clinical and Molecular Genetic Spectrum of Congenital Deficiency of the Leptin Receptor. N. Engl. J. Med. 2007, 356, 237–247. [Google Scholar] [CrossRef] [Scilit]
  22. Shi, L.; Jiang, Z.; Zhang, L. Childhood Obesity and Central Precocious Puberty. Front. Endocrinol. 2022, 13, 1056871. [Google Scholar] [CrossRef] [Scilit]
  23. Barabás, K.; Szabó-Meleg, E.; Ábrahám, I.M. Effect of Inflammation on Female Gonadotropin-Releasing Hormone (GnRH) Neurons: Mechanisms and Consequences. Int. J. Mol. Sci. 2020, 21, 529. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Watanobe, H.; Hayakawa, Y. Hypothalamic Interleukin-1β and Tumor Necrosis Factor-α, But Not Interleukin-6, Mediate the Endotoxin-Induced Suppression of the Reproductive Axis in Rats. Endocrinology 2003, 144, 4868–4875. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Lainez, N.M.; Coss, D. Obesity, Neuroinflammation, and Reproductive Function. Endocrinology 2019, 160, 2719–2736. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Soliman, A.T.; Alaaraj, N.; De Sanctis, V.; Hamed, N.; Alyafei, F.; Ahmed, S. Long-Term Health Consequences of Central Precocious/Early Puberty (CPP) and Treatment with Gn-RH Analogue: A Short Update: Long Term Consequences of Precocious Puberty. Acta Biomed. Atenei Parm. 2023, 94, e2023222. [Google Scholar] [CrossRef] [Scilit]
  27. Brito, V.N.; Spinola-Castro, A.M.; Kochi, C.; Kopacek, C.; Silva, P.C.A.D.; Guerra-Júnior, G. Central Precocious Puberty: Revisiting the Diagnosis and Therapeutic Management. Arch. Endocrinol. Metab. 2016, 60, 163–172. [Google Scholar] [CrossRef] [Scilit]
  28. Cantas-Orsdemir, S.; Eugster, E.A. Update on Central Precocious Puberty: From Etiologies to Outcomes. Expert Rev. Endocrinol. Metab. 2019, 14, 123–130. [Google Scholar] [CrossRef] [Scilit]
  29. Fanaki, M.; Michala, L.; Nazari, E.; Daskalakis, G. Central Precocious Puberty During the COVID-19 Pandemic Period: A Systematic Review of Literature. Cureus 2024, 16, e71002. [Google Scholar] [CrossRef] [Scilit]
  30. Zhang, J.; Xu, J.; Tang, X.; Wu, R. Comparison of Central Precocious Puberty Frequency before and during COVID-19: A Systematic Review and Meta-Analysis. BMC Endocr. Disord. 2024, 24, 219. [Google Scholar] [CrossRef] [Scilit]
  31. Root, A.W. Precocious Puberty. Pediatr. Rev. 2000, 21, 10–19. [Google Scholar] [CrossRef] [Scilit]
  32. Gangat, M.; Radovick, S. Precocious Puberty. Minerva Pediatr. 2021, 72, 491–500. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Predieri, B.; Iughetti, L.; Bernasconi, S.; Street, M.E. Endocrine Disrupting Chemicals’ Effects in Children: What We Know and What We Need to Learn? Int. J. Mol. Sci. 2022, 23, 11899. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Zevin, E.L.; Eugster, E.A. Central Precocious Puberty: A Review of Diagnosis, Treatment, and Outcomes. Lancet Child Adolesc. Health 2023, 7, 886–896. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Kim, S.H.; Huh, K.; Won, S.; Lee, K.-W.; Park, M.-J. A Significant Increase in the Incidence of Central Precocious Puberty among Korean Girls from 2004 to 2010. PLoS ONE 2015, 10, e0141844. [Google Scholar] [CrossRef] [Scilit]
  36. Talarico, V.; Rodio, M.B.; Viscomi, A.; Galea, E.; Galati, M.C.; Raiola, G. The Role of Pelvic Ultrasound for the Diagnosis and Management of Central Precocious Puberty: An Update. Acta Biomed. Atenei Parm. 2021, 92, e2021480. [Google Scholar] [CrossRef] [Scilit]
  37. Eugster, E.A. Treatment of Central Precocious Puberty. J. Endocr. Soc. 2019, 3, 965–972. [Google Scholar] [CrossRef] [Scilit]
  38. Corripio, R.; Soriano-Guillén, L.; Herrero, F.-J.; Castro-Feijoó, L.; Escribano, A.; Sol-Ventura, P.; Espino, R.; Vela, A.; Labarta, J.-I. The Spanish PUBERE Group; et al. Adult Height in Girls with Idiopathic Central Precocious Puberty Treated with Triptorelin. Front. Endocrinol. 2024, 15, 1498726. [Google Scholar] [CrossRef] [Scilit]
  39. Sisk-Hackworth, L.; Kelley, S.T.; Thackray, V.G. Sex, Puberty, and the Gut Microbiome. Reprod. Camb. Engl. 2023, 165, R61–R74. [Google Scholar] [CrossRef] [Scilit]
  40. Latronico, A.C.; Brito, V.N.; Carel, J.-C. Causes, Diagnosis, and Treatment of Central Precocious Puberty. Lancet Diabetes Endocrinol. 2016, 4, 265–274. [Google Scholar] [CrossRef] [Scilit]
  41. Pantazi, A.C.; Balasa, A.L.; Mihai, C.M.; Chisnoiu, T.; Lupu, V.V.; Kassim, M.A.K.; Mihai, L.; Frecus, C.E.; Chirila, S.I.; Lupu, A.; et al. Development of Gut Microbiota in the First 1000 Days after Birth and Potential Interventions. Nutrients 2023, 15, 3647. [Google Scholar] [CrossRef] [Scilit]
  42. Davis, E.C.; Monaco, C.L.; Insel, R.; Järvinen, K.M. Gut Microbiome in the First 1000 Days and Risk for Childhood Food Allergy. Ann. Allergy. Asthma. Immunol. 2024, 133, 252–261. [Google Scholar] [CrossRef] [Scilit]
  43. Yuan, X.; Chen, R.; Zhang, Y.; Lin, X.; Yang, X. Gut Microbiota: Effect of Pubertal Status. BMC Microbiol. 2020, 20, 334. [Google Scholar] [CrossRef] [Scilit]
  44. Del Castillo-Izquierdo, Á.; Mayneris-Perxachs, J.; Fernández-Real, J.M. Bidirectional Relationships between the Gut Microbiome and Sexual Traits. Am. J. Physiol.-Cell Physiol. 2022, 322, C1223–C1229. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. Li, Y.; Shen, L.; Huang, C.; Li, X.; Chen, J.; Li, S.C.; Shen, B. Altered Nitric Oxide Induced by Gut Microbiota Reveals the Connection between Central Precocious Puberty and Obesity. Clin. Transl. Med. 2021, 11, e299. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Mazgaj, M. Diagnostyka Ultrasonograficzna Narządów Jamy Brzusznej w Przypadku Przedwczesnego Dojrzewania Płciowego u Dziewcząt. J. Ultrason. 2013, 13, 418–424. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Calcaterra, V.; Klersy, C.; Vinci, F.; Regalbuto, C.; Dobbiani, G.; Montalbano, C.; Pelizzo, G.; Albertini, R.; Larizza, D. Rapid Progressive Central Precocious Puberty: Diagnostic and Predictive Value of Basal Sex Hormone Levels and Pelvic Ultrasound. J. Pediatr. Endocrinol. Metab. 2020, 33, 785–791. [Google Scholar] [CrossRef] [Scilit]
  48. Santos-Marcos, J.A.; Mora-Ortiz, M.; Tena-Sempere, M.; Lopez-Miranda, J.; Camargo, A. Interaction between Gut Microbiota and Sex Hormones and Their Relation to Sexual Dimorphism in Metabolic Diseases. Biol. Sex Differ. 2023, 14, 4. [Google Scholar] [CrossRef] [Scilit]
  49. Dong, G.; Zhang, J.; Yang, Z.; Feng, X.; Li, J.; Li, D.; Huang, M.; Li, Y.; Qiu, M.; Lu, X.; et al. The Association of Gut Microbiota With Idiopathic Central Precocious Puberty in Girls. Front. Endocrinol. 2020, 10, 941. [Google Scholar] [CrossRef] [Scilit]
  50. Bangalore Krishna, K.; Fuqua, J.S.; Rogol, A.D.; Klein, K.O.; Popovic, J.; Houk, C.P.; Charmandari, E.; Lee, P.A. Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium. Horm. Res. Paediatr. 2019, 91, 357–372. [Google Scholar] [CrossRef] [Scilit]
  51. Yeh, S.-N.; Ting, W.-H.; Huang, C.-Y.; Huang, S.-K.; Lee, Y.-C.; Chua, W.-K.; Lin, C.-H.; Cheng, B.-W.; Lee, Y.-J. Diagnostic Evaluation of Central Precocious Puberty in Girls. Pediatr. Neonatol. 2021, 62, 187–194. [Google Scholar] [CrossRef] [Scilit]
  52. Huang, C.; Liu, H.; Yang, W.; Li, Y.; Wu, B.; Chen, J.; Yang, Z.; Liao, C.; Liu, L.; Zhang, X. Distinct Gut Microbiota Structure and Function of Children with Idiopathic Central and Peripheral Precocious Puberty. Int. J. Endocrinol. 2022, 2022, 7175250. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Yatsunenko, T.; Rey, F.E.; Manary, M.J.; Trehan, I.; Dominguez-Bello, M.G.; Contreras, M.; Magris, M.; Hidalgo, G.; Baldassano, R.N.; Anokhin, A.P.; et al. Human Gut Microbiome Viewed across Age and Geography. Nature 2012, 486, 222–227. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Xu, C.; Zhu, H.; Qiu, P. Aging Progression of Human Gut Microbiota. BMC Microbiol. 2019, 19, 236. [Google Scholar] [CrossRef] [Scilit]
  55. Wang, Y.; Jin, C.; Li, H.; Liang, X.; Zhao, C.; Wu, N.; Yue, M.; Zhao, L.; Yu, H.; Wang, Q.; et al. Gut Microbiota-Metabolite Interactions Meditate the Effect of Dietary Patterns on Precocious Puberty. iScience 2024, 27, 109887. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Strati, F.; Di Paola, M.; Stefanini, I.; Albanese, D.; Rizzetto, L.; Lionetti, P.; Calabrò, A.; Jousson, O.; Donati, C.; Cavalieri, D.; et al. Age and Gender Affect the Composition of Fungal Population of the Human Gastrointestinal Tract. Front. Microbiol. 2016, 7, 1227. [Google Scholar] [CrossRef] [Scilit]
  57. Ringel-Kulka, T.; Cheng, J.; Ringel, Y.; Salojärvi, J.; Carroll, I.; Palva, A.; De Vos, W.M.; Satokari, R. Intestinal Microbiota in Healthy U.S. Young Children and Adults—A High Throughput Microarray Analysis. PLoS ONE 2013, 8, e64315. [Google Scholar] [CrossRef] [Scilit]
  58. Ervin, S.M.; Li, H.; Lim, L.; Roberts, L.R.; Liang, X.; Mani, S.; Redinbo, M.R. Gut Microbial β-Glucuronidases Reactivate Estrogens as Components of the Estrobolome That Reactivate Estrogens. J. Biol. Chem. 2019, 294, 18586–18599. [Google Scholar] [CrossRef] [Scilit]
  59. Larnder, A.H.; Manges, A.R.; Murphy, R.A. The Estrobolome: Estrogen-metabolizing Pathways of the Gut Microbiome and Their Relation to Breast Cancer. Int. J. Cancer 2025, 157, 599–613. [Google Scholar] [CrossRef] [Scilit]
  60. Bucurica, S.; Lupanciuc, M.; Ionita-Radu, F.; Stefan, I.; Munteanu, A.E.; Anghel, D.; Jinga, M.; Gaman, E.L. Estrobolome and Hepatocellular Adenomas—Connecting the Dots of the Gut Microbial β-Glucuronidase Pathway as a Metabolic Link. Int. J. Mol. Sci. 2023, 24, 16034. [Google Scholar] [CrossRef] [Scilit]
  61. Agans, R.; Rigsbee, L.; Kenche, H.; Michail, S.; Khamis, H.J.; Paliy, O. Distal Gut Microbiota of Adolescent Children Is Different from That of Adults: Gut Microbiota of Adolescents Differs from That of Adults. FEMS Microbiol. Ecol. 2011, 77, 404–412. [Google Scholar] [CrossRef] [Scilit]
  62. Lephart, E.D.; Naftolin, F. Estrogen Action and Gut Microbiome Metabolism in Dermal Health. Dermatol. Ther. 2022, 12, 1535–1550. [Google Scholar] [CrossRef] [Scilit]
  63. Calcaterra, V.; Rossi, V.; Massini, G.; Regalbuto, C.; Hruby, C.; Panelli, S.; Bandi, C.; Zuccotti, G. Precocious Puberty and Microbiota: The Role of the Sex Hormone–Gut Microbiome Axis. Front. Endocrinol. 2022, 13, 1000919. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Huang, X.; Chen, J.; Zou, H.; Huang, P.; Luo, H.; Li, H.; Cai, Y.; Liu, L.; Li, Y.; He, X.; et al. Gut Microbiome Combined with Metabolomics Reveals Biomarkers and Pathways in Central Precocious Puberty. J. Transl. Med. 2023, 21, 316. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Lange, O.; Proczko-Stepaniak, M.; Mika, A. Short-Chain Fatty Acids-A Product of the Microbiome and Its Participation in Two-Way Communication on the Microbiome-Host Mammal Line. Curr. Obes. Rep. 2023, 12, 108–126. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Enck, P.; Zimmermann, K.; Rusch, K.; Schwiertz, A.; Klosterhalfen, S.; Frick, J.S. The Effects of Maturation on the Colonic Microflora in Infancy and Childhood. Gastroenterol. Res. Pract. 2009, 2009, 752401. [Google Scholar] [CrossRef] [Scilit]
  67. Fan, Y.; Pedersen, O. Gut Microbiota in Human Metabolic Health and Disease. Nat. Rev. Microbiol. 2021, 19, 55–71. [Google Scholar] [CrossRef] [Scilit]
  68. Santos-Marcos, J.A.; Rangel-Zuñiga, O.A.; Jimenez-Lucena, R.; Quintana-Navarro, G.M.; Garcia-Carpintero, S.; Malagon, M.M.; Landa, B.B.; Tena-Sempere, M.; Perez-Martinez, P.; Lopez-Miranda, J.; et al. Influence of Gender and Menopausal Status on Gut Microbiota. Maturitas 2018, 116, 43–53. [Google Scholar] [CrossRef] [Scilit]
  69. Sommer, F.; Bäckhed, F. The Gut Microbiota—Masters of Host Development and Physiology. Nat. Rev. Microbiol. 2013, 11, 227–238. [Google Scholar] [CrossRef] [Scilit]
  70. Yoon, K.; Kim, N. Roles of Sex Hormones and Gender in the Gut Microbiota. J. Neurogastroenterol. Motil. 2021, 27, 314–325. [Google Scholar] [CrossRef] [Scilit]
  71. Tremaroli, V.; Bäckhed, F. Functional Interactions between the Gut Microbiota and Host Metabolism. Nature 2012, 489, 242–249. [Google Scholar] [CrossRef] [Scilit]
  72. Elderman, M.; Hugenholtz, F.; Belzer, C.; Boekschoten, M.; Van Beek, A.; De Haan, B.; Savelkoul, H.; De Vos, P.; Faas, M. Sex and Strain Dependent Differences in Mucosal Immunology and Microbiota Composition in Mice. Biol. Sex Differ. 2018, 9, 26. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  73. Qi, X.; Yun, C.; Pang, Y.; Qiao, J. The Impact of the Gut Microbiota on the Reproductive and Metabolic Endocrine System. Gut Microbes 2021, 13, 1894070. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  74. Hopkins, M.J.; Sharp, R.; Macfarlane, G.T. Variation in Human Intestinal Microbiota with Age. Dig. Liver Dis. 2002, 34, S12–S18. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  75. Rogers, I.S.; Northstone, K.; Dunger, D.B.; Cooper, A.R.; Ness, A.R.; Emmett, P.M. Diet throughout Childhood and Age at Menarche in a Contemporary Cohort of British Girls. Public Health Nutr. 2010, 13, 2052–2063. [Google Scholar] [CrossRef] [Scilit]
  76. Chakraborti, C.K. New-Found Link between Microbiota and Obesity. World J. Gastrointest. Pathophysiol. 2015, 6, 110. [Google Scholar] [CrossRef] [Scilit]
  77. Delzenne, N.M.; Cani, P.D. Interaction Between Obesity and the Gut Microbiota: Relevance in Nutrition. Annu. Rev. Nutr. 2011, 31, 15–31. [Google Scholar] [CrossRef] [Scilit]
  78. Wang, M.; Zhang, Y.; Miller, D.; Rehman, N.O.; Cheng, X.; Yeo, J.-Y.; Joe, B.; Hill, J.W. Microbial Reconstitution Reverses Early Female Puberty Induced by Maternal High-Fat Diet During Lactation. Endocrinology 2020, 161, bqz041. [Google Scholar] [CrossRef] [Scilit]
  79. Bao, M.; Wu, R.; Li, J.; Tang, R.; Song, C. Research Summary, Possible Mechanisms and Perspectives of Gut Microbiota Changes Causing Precocious Puberty. Front. Nutr. 2025, 12, 1596654. [Google Scholar] [CrossRef] [Scilit]
  80. Sun, Y.; Liu, H.; Mu, C.; Liu, P.; Hao, C.; Xin, Y. Early Puberty: A Review on Its Role as a Risk Factor for Metabolic and Mental Disorders. Front. Pediatr. 2024, 12, 1326864. [Google Scholar] [CrossRef] [Scilit]
  81. Cussotto, S.; Sandhu, K.V.; Dinan, T.G.; Cryan, J.F. The Neuroendocrinology of the Microbiota-Gut-Brain Axis: A Behavioural Perspective. Front. Neuroendocrinol. 2018, 51, 80–101. [Google Scholar] [CrossRef] [Scilit]
  82. Singh, V.; Lee, G.; Son, H.; Koh, H.; Kim, E.S.; Unno, T.; Shin, J.-H. Butyrate Producers, “The Sentinel of Gut”: Their Intestinal Significance with and beyond Butyrate, and Prospective Use as Microbial Therapeutics. Front. Microbiol. 2023, 13, 1103836. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  83. Zhai, S.; Qin, S.; Li, L.; Zhu, L.; Zou, Z.; Wang, L. Dietary Butyrate Suppresses Inflammation through Modulating Gut Microbiota in High-Fat Diet-Fed Mice. FEMS Microbiol. Lett. 2019, 366, fnz153. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  84. Rodríguez Mazariegos, J.R.; Nam, N.N.; Bo, T.; Wang, D.; Hsu, J.-W.; Chen, Y.-C. Precocious Puberty and Gut Microbiome: A Systematic Review and Meta-Analysis. Pediatr. Res. 2025. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  85. Bo, T.; Liu, M.; Tang, L.; Lv, J.; Wen, J.; Wang, D. Effects of High-Fat Diet During Childhood on Precocious Puberty and Gut Microbiota in Mice. Front. Microbiol. 2022, 13, 930747. [Google Scholar] [CrossRef] [Scilit]
  86. Wu, N.; Jiang, X.; Wang, Y.; Zhang, M.; Yue, M.; Chen, F.; Wu, W.; Liu, Y.; Wang, Q.; Zhang, L. Gut Microbiota Alterations Modulate High-Fat Diet-Induced Precocious Puberty. Microbiol. Spectr. 2025, 13, e03264-24. [Google Scholar] [CrossRef] [Scilit]
  87. Houtman, T.A.; Eckermann, H.A.; Smidt, H.; De Weerth, C. Gut Microbiota and BMI throughout Childhood: The Role of Firmicutes, Bacteroidetes, and Short-Chain Fatty Acid Producers. Sci. Rep. 2022, 12, 3140. [Google Scholar] [CrossRef] [Scilit]
  88. Facchin, S.; Bertin, L.; Bonazzi, E.; Lorenzon, G.; De Barba, C.; Barberio, B.; Zingone, F.; Maniero, D.; Scarpa, M.; Ruffolo, C.; et al. Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications. Life 2024, 14, 559. [Google Scholar] [CrossRef] [Scilit]
  89. Morrison, D.J.; Preston, T. Formation of Short Chain Fatty Acids by the Gut Microbiota and Their Impact on Human Metabolism. Gut Microbes 2016, 7, 189–200. [Google Scholar] [CrossRef] [Scilit]
  90. Vinolo, M.A.R.; Rodrigues, H.G.; Nachbar, R.T.; Curi, R. Regulation of Inflammation by Short Chain Fatty Acids. Nutrients 2011, 3, 858–876. [Google Scholar] [CrossRef] [Scilit]
  91. Hosseini, E.; Grootaert, C.; Verstraete, W.; Van De Wiele, T. Propionate as a Health-Promoting Microbial Metabolite in the Human Gut. Nutr. Rev. 2011, 69, 245–258. [Google Scholar] [CrossRef] [Scilit]
  92. Lin, H.V.; Frassetto, A.; Kowalik, E.J., Jr.; Nawrocki, A.R.; Lu, M.M.; Kosinski, J.R.; Hubert, J.A.; Szeto, D.; Yao, X.; Forrest, G.; et al. Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms. PLoS ONE 2012, 7, e35240. [Google Scholar] [CrossRef] [Scilit]
  93. Novaira, H.J.; Ng, Y.; Wolfe, A.; Radovick, S. Kisspeptin Increases GnRH mRNA Expression and Secretion in GnRH Secreting Neuronal Cell Lines. Mol. Cell. Endocrinol. 2009, 311, 126–134. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  94. O’Riordan, K.J.; Collins, M.K.; Moloney, G.M.; Knox, E.G.; Aburto, M.R.; Fülling, C.; Morley, S.J.; Clarke, G.; Schellekens, H.; Cryan, J.F. Short Chain Fatty Acids: Microbial Metabolites for Gut-Brain Axis Signalling. Mol. Cell. Endocrinol. 2022, 546, 111572. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  95. Xiao, L.; Wang, J.; Zheng, J.; Li, X.; Zhao, F. Deterministic Transition of Enterotypes Shapes the Infant Gut Microbiome at an Early Age. Genome Biol. 2021, 22, 243. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  96. Cho, K.Y. Association of Gut Microbiota with Obesity in Children and Adolescents. Clin. Exp. Pediatr. 2023, 66, 148–154. [Google Scholar] [CrossRef] [Scilit]
  97. Pryde, S.E.; Duncan, S.H.; Hold, G.L.; Stewart, C.S.; Flint, H.J. The Microbiology of Butyrate Formation in the Human Colon. FEMS Microbiol. Lett. 2002, 217, 133–139. [Google Scholar] [CrossRef]
  98. Ríos-Covián, D.; Ruas-Madiedo, P.; Margolles, A.; Gueimonde, M.; De Los Reyes-Gavilán, C.G.; Salazar, N. Intestinal Short Chain Fatty Acids and Their Link with Diet and Human Health. Front. Microbiol. 2016, 7, 185. [Google Scholar] [CrossRef] [Scilit]
  99. Nakayama, J.; Watanabe, K.; Jiang, J.; Matsuda, K.; Chao, S.-H.; Haryono, P.; La-ongkham, O.; Sarwoko, M.-A.; Sujaya, I.N.; Zhao, L.; et al. Diversity in Gut Bacterial Community of School-Age Children in Asia. Sci. Rep. 2015, 5, 8397. [Google Scholar] [CrossRef] [Scilit]
  100. Parker, B.J.; Wearsch, P.A.; Veloo, A.C.M.; Rodriguez-Palacios, A. The Genus Alistipes: Gut Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health. Front. Immunol. 2020, 11, 906. [Google Scholar] [CrossRef] [Scilit]
  101. Duncan, S.H.; Belenguer, A.; Holtrop, G.; Johnstone, A.M.; Flint, H.J.; Lobley, G.E. Reduced Dietary Intake of Carbohydrates by Obese Subjects Results in Decreased Concentrations of Butyrate and Butyrate-Producing Bacteria in Feces. Appl. Environ. Microbiol. 2007, 73, 1073–1078. [Google Scholar] [CrossRef] [Scilit]
  102. Pérez-Navero, J.L.; Benítez-Sillero, J.D.; Gil-Campos, M.; Guillén-del Castillo, M.; Tasset, I.; Túnez, I. Changes in oxidative stress biomarkers induced by puberty. An. Pediatr. 2009, 70, 424–428. [Google Scholar] [CrossRef] [Scilit]
  103. Tett, A.; Huang, K.D.; Asnicar, F.; Fehlner-Peach, H.; Pasolli, E.; Karcher, N.; Armanini, F.; Manghi, P.; Bonham, K.; Zolfo, M.; et al. The Prevotella Copri Complex Comprises Four Distinct Clades Underrepresented in Westernized Populations. Cell Host Microbe 2019, 26, 666–679.e7. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  104. Wang, L.; Tang, J.; Wang, L.; Tan, F.; Song, H.; Zhou, J.; Li, F. Oxidative Stress in Oocyte Aging and Female Reproduction. J. Cell. Physiol. 2021, 236, 7966–7983. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  105. Liu, C.; Zhou, S.; Li, Y.; Yin, X.; Li, P. Metabolomic Disorders Caused by an Imbalance in the Gut Microbiota Are Associated with Central Precocious Puberty. Front. Endocrinol. 2024, 15, 1481364. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  106. Sandhu, J.; Ben-Shlomo, Y.; Cole, T.J.; Holly, J.; Davey Smith, G. The Impact of Childhood Body Mass Index on Timing of Puberty, Adult Stature and Obesity: A Follow-up Study Based on Adolescent Anthropometry Recorded at Christ’s Hospital (1936–1964). Int. J. Obes. 2006, 30, 14–22. [Google Scholar] [CrossRef] [Scilit]
  107. Calcaterra, V.; Verduci, E.; Magenes, V.C.; Pascuzzi, M.C.; Rossi, V.; Sangiorgio, A.; Bosetti, A.; Zuccotti, G.; Mameli, C. The Role of Pediatric Nutrition as a Modifiable Risk Factor for Precocious Puberty. Life 2021, 11, 1353. [Google Scholar] [CrossRef] [Scilit]
  108. Lakshmanan, A.P.; Al Zaidan, S.; Bangarusamy, D.K.; Al-Shamari, S.; Elhag, W.; Terranegra, A. Increased Relative Abundance of Ruminoccocus Is Associated With Reduced Cardiovascular Risk in an Obese Population. Front. Nutr. 2022, 9, 849005. [Google Scholar] [CrossRef] [Scilit]
  109. Pai, A.H.-Y.; Wang, Y.-W.; Lu, P.-C.; Wu, H.-M.; Xu, J.-L.; Huang, H.-Y. Gut Microbiome–Estrobolome Profile in Reproductive-Age Women with Endometriosis. Int. J. Mol. Sci. 2023, 24, 16301. [Google Scholar] [CrossRef] [Scilit]
  110. Valsamakis, G.; Arapaki, A.; Balafoutas, D.; Charmandari, E.; Vlahos, N.F. Diet-Induced Hypothalamic Inflammation, Phoenixin, and Subsequent Precocious Puberty. Nutrients 2021, 13, 3460. [Google Scholar] [CrossRef] [Scilit]
  111. Kiess, W.; Hoppmann, J.; Gesing, J.; Penke, M.; Körner, A.; Kratzsch, J.; Pfaeffle, R. Puberty–Genes, Environment and Clinical Issues. J. Pediatr. Endocrinol. Metab. 2016, 29, 1229–1231. [Google Scholar] [CrossRef] [Scilit]
  112. Valdearcos, M.; Robblee, M.M.; Benjamin, D.I.; Nomura, D.K.; Xu, A.W.; Koliwad, S.K. Microglia Dictate the Impact of Saturated Fat Consumption on Hypothalamic Inflammation and Neuronal Function. Cell Rep. 2014, 9, 2124–2138. [Google Scholar] [CrossRef] [Scilit]
  113. Fujioka, H.; Kakehashi, C.; Funabashi, T.; Akema, T. Immunohistochemical Evidence for the Relationship between Microglia and GnRH Neurons in the Preoptic Area of Ovariectomized Rats with and without Steroid Replacement. Endocr. J. 2013, 60, 191–196. [Google Scholar] [CrossRef] [Scilit]
  114. Chen, T.; Chen, C.; Wu, H.; Chen, X.; Xie, R.; Wang, F.; Sun, H.; Chen, L. Overexpression of P53 Accelerates Puberty in High-Fat Diet–Fed Mice through Lin28/Let-7 System. Exp. Biol. Med. 2021, 246, 66–71. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  115. Yosten, G.L.C.; Lyu, R.-M.; Hsueh, A.J.W.; Avsian-Kretchmer, O.; Chang, J.-K.; Tullock, C.W.; Dun, S.L.; Dun, N.; Samson, W.K. A Novel Reproductive Peptide, Phoenixin. J. Neuroendocrinol. 2013, 25, 206–215. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  116. Gu, Q.; Du, Q.; Xia, L.; Lu, X.; Wan, X.; Shao, Y.; He, J.; Wu, P. Mechanistic Insights into EGCG’s Preventive Effects on Obesity-Induced Precocious Puberty through Multi-Omics Analyses. Food Funct. 2024, 15, 11169–11185. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  117. Rodríguez-Daza, M.C.; Pulido-Mateos, E.C.; Lupien-Meilleur, J.; Guyonnet, D.; Desjardins, Y.; Roy, D. Polyphenol-Mediated Gut Microbiota Modulation: Toward Prebiotics and Further. Front. Nutr. 2021, 8, 689456. [Google Scholar] [CrossRef] [Scilit]
  118. Cowan, C.S.M.; Richardson, R. Early-life Stress Leads to Sex-dependent Changes in Pubertal Timing in Rats That Are Reversed by a Probiotic Formulation. Dev. Psychobiol. 2019, 61, 679–687. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.